Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Hypertension, Pulmonary

ClinicalTrials.gov lists 1,600 trials for Hypertension, Pulmonary or a narrower condition beneath it. Actelion has the most among industry and government lead sponsors, with 72.

MeSH D006976 Respiratory Tract Diseases C08 C14
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 133 Phase 1/2 Phase 1/2 36 Phase 2 Phase 2 220 Phase 2/3 Phase 2/3 29 Phase 3 Phase 3 186 Phase 4 Phase 4 123 Not applicable Not applicable 336 Observational Observational 527 Phase 1 Phase 1 133 Phase 1/2 Phase 1/2 36 Phase 2 Phase 2 220 Phase 2/3 Phase 2/3 29 Phase 3 Phase 3 186 Phase 4 Phase 4 123 Not applicable Not applicable 336 Observational Observational 527

Trials per phase

1 more section with rows

1,011 of the 1,600 trials are tagged with Hypertension, Pulmonary itself; the rest are tagged with a narrower condition beneath it.

Get the Hypertension, Pulmonary report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Hypertension, Pulmonary trials start? (34)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 4 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 89

1991: 2 trials (Observational 1, Not applicable 1) 1992: 1 trials (Observational 1) 1993: 3 trials (Observational 2, Phase 4 1) 1994: 1 trials (Observational 1) 1995: 1 trials (Phase 3 1) 1998: 6 trials (Observational 1, Phase 3 2, Phase 2 3) 1999: 2 trials (Phase 4 1, Phase 2 1) 2000: 2 trials (Observational 1, Phase 3 1) 2001: 3 trials (Observational 1, Phase 3 1, Phase 1 1) 2002: 7 trials (Not applicable 1, Phase 4 1, Phase 3 2, Phase 2 3) 2003: 15 trials (Observational 2, Phase 4 4, Phase 3 7, Phase 2 2) 2004: 13 trials (Observational 3, Phase 4 3, Phase 3 5, Phase 2 2) 2005: 27 trials (Observational 6, Not applicable 4, Phase 4 3, Phase 3 7, Phase 2 4, Phase 1/2 1, Phase 1 2) 2006: 52 trials (Observational 14, Not applicable 5, Phase 4 8, Phase 3 10, Phase 2/3 2, Phase 2 8, Phase 1/2 1, Phase 1 4) 2007: 41 trials (Observational 16, Not applicable 3, Phase 4 7, Phase 3 6, Phase 2/3 1, Phase 2 6, Phase 1 2) 2008: 59 trials (Observational 14, Not applicable 6, Phase 4 9, Phase 3 13, Phase 2/3 2, Phase 2 9, Phase 1 6) 2009: 56 trials (Observational 15, Not applicable 4, Phase 4 6, Phase 3 12, Phase 2/3 1, Phase 2 11, Phase 1/2 2, Phase 1 5) 2010: 77 trials (Observational 23, Not applicable 13, Phase 4 7, Phase 3 9, Phase 2/3 1, Phase 2 15, Phase 1/2 2, Phase 1 7) 2011: 77 trials (Observational 23, Not applicable 10, Phase 4 8, Phase 3 11, Phase 2/3 3, Phase 2 12, Phase 1/2 3, Phase 1 7) 2012: 69 trials (Observational 20, Not applicable 12, Phase 4 10, Phase 3 7, Phase 2 12, Phase 1/2 4, Phase 1 4) 2013: 70 trials (Observational 28, Not applicable 7, Phase 4 3, Phase 3 14, Phase 2/3 1, Phase 2 7, Phase 1 10) 2014: 61 trials (Observational 23, Not applicable 11, Phase 4 8, Phase 3 5, Phase 2/3 1, Phase 2 9, Phase 1/2 2, Phase 1 2) 2015: 62 trials (Observational 25, Not applicable 14, Phase 4 6, Phase 3 3, Phase 2 6, Phase 1/2 1, Phase 1 7) 2016: 78 trials (Observational 25, Not applicable 18, Phase 4 7, Phase 3 8, Phase 2/3 3, Phase 2 10, Phase 1/2 1, Phase 1 6) 2017: 88 trials (Observational 38, Not applicable 19, Phase 4 6, Phase 3 5, Phase 2/3 3, Phase 2 10, Phase 1/2 1, Phase 1 6) 2018: 89 trials (Observational 23, Not applicable 30, Phase 4 1, Phase 3 10, Phase 2/3 2, Phase 2 10, Phase 1/2 1, Phase 1 12) 2019: 74 trials (Observational 20, Not applicable 18, Phase 4 3, Phase 3 5, Phase 2 15, Phase 1/2 3, Phase 1 10) 2020: 56 trials (Observational 25, Not applicable 11, Phase 3 4, Phase 2 7, Phase 1/2 1, Phase 1 8) 2021: 84 trials (Observational 35, Not applicable 22, Phase 4 3, Phase 3 7, Phase 2/3 2, Phase 2 6, Phase 1/2 2, Phase 1 7) 2022: 52 trials (Observational 15, Not applicable 16, Phase 4 2, Phase 3 4, Phase 2 10, Phase 1 5) 2023: 80 trials (Observational 27, Not applicable 29, Phase 4 3, Phase 3 5, Phase 2/3 3, Phase 2 10, Phase 1/2 1, Phase 1 2) 2024: 85 trials (Observational 25, Not applicable 32, Phase 4 3, Phase 3 6, Phase 2/3 1, Phase 2 8, Phase 1/2 3, Phase 1 7) 2025: 86 trials (Observational 43, Not applicable 16, Phase 4 5, Phase 3 2, Phase 2/3 1, Phase 2 12, Phase 1/2 1, Phase 1 6)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 103
2025 86
2024 85
2023 80
2022 52
2021 84
2020 56
2019 74
2018 89
2017 88

Showing 10 of 34 earlier years.

Start your 14-day trial Email me all 34 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 120 trials starting in 2026 and about 95 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 15 percent and ran about 1 percent high against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. The part-way figures are from forecasts that used a multiple fitted only on earlier years. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 105 trials still running at the 2026-10-09 snapshot; registered median of 26 months across 975 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Hypertension, Pulmonary trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 133
Phase 1/2 36
Phase 2 220
Phase 2/3 29
Phase 3 186
Phase 4 123
Not applicable 336
Observational 527
Expanded access 10

How many Hypertension, Pulmonary trials are recruiting? (11)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 80
Recruiting 196
Enrolling by invitation 15
Active, not recruiting 45
Available 4

Showing 5 of 11 statuses.

Start your 14-day trial Email me all 11 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Hypertension, Pulmonary trials? (8)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Actelion 72
United Therapeutics 60
Bayer 45
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. 23
National Heart, Lung, and Blood Institute (NHLBI) 20

Showing 5 of 8 sponsors.

Start your 14-day trial Email me all 8 sponsors as a PDF

Which drugs are being tested for Hypertension, Pulmonary? (8)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
SILDENAFIL 76
Treprostinil 44
BOSENTAN 37
Ambrisentan 31
ILOPROST 26

Showing 5 of 8 drugs.

Start your 14-day trial Email me all 8 drugs as a PDF

Interventions as named in the registry (7)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Riociguat Pill 29
Tadalafil Pill 27
Macitentan Dose 3 25
Sotatercept Autoinjector 21
Inhaled Nitric Oxide (iNO) use 15

Showing 5 of 7 interventions.

Start your 14-day trial Email me all 7 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Hypertension, Pulmonary trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Pneumonia 899 94
Right ventricular failure 756 77
Pulmonary hypertension 602 51
Pulmonary arterial hypertension 486 61
Cardiac failure 478 49

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Hypertension, Pulmonary? (1,564)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
The Role of Genetics in Congenital Heart Disease-Associated Pulmonary Arterial Hypertension. Pediatric cardiology 2026 Yes
A long-term follow-up study of sotatercept for treatment of pulmonary arterial hypertension: interim results of SOTERIA. The European respiratory journal 2025 Yes
Macitentan and Tadalafil Combination Therapy in Patients with Pulmonary Arterial Hypertension and Cardiovascular Comorbidities: Real-World Evidence from OPUS and OrPHeUS. Advances in therapy 2025 Yes
Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis. The New England journal of medicine 2025 Yes
Fragmented QRS complex could predict all-cause mortality in patients with connective tissue disease-associated pulmonary arterial hypertension. Rheumatology (Oxford, England) 2025 Yes

Showing 5 of 1,564 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Sub-conditions in MeSH (3)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages